

Customized FORM PTO-1390		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY DOCKET NO P07484US00/BAS
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO 10/030055
INTERNATIONAL APPLICATION NO. PCT/EP00/06730	INTERNATIONAL FILING DATE 07 JULY 2000	PRIORITY DATE CLAIMED 09 JULY 1999		
TITLE OF INVENTION: METHOD FOR THE DIAGNOSIS OR THE PROGNOSIS OF ALZHEIMER DISEASE ...				
APPLICANT(S) FOR DO/EO/US: MOOSER, Vincent et al.				
Applicant herewith submits to the US Designated/Elected Office (DO/EO/US) the following items and other information				
<input checked="" type="checkbox"/> 1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> 2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 USC 371. <input checked="" type="checkbox"/> 3. This express request to begin national examination procedures (35 USC 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 USC 371(b) and PCT Art. 22 and 39(1). <input checked="" type="checkbox"/> 4. A proper Demand for International Preliminary Examination was made by the 19 th month from the earliest claimed priority date. <input checked="" type="checkbox"/> 5. A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) <input type="checkbox"/> a. is transmitted herewith (required only if not transmitted by the International Bureau). <input checked="" type="checkbox"/> b. has been transmitted by the International Bureau. <input type="checkbox"/> c. is not required, as the application was filed in the United States Receiving Office (RO/US). <input type="checkbox"/> 6. A translation of the International Application into English (35 U.S.C. 371(c)(2)). <input checked="" type="checkbox"/> 7. Amendments to the claims of the International Appln. under PCT Article 19 (35 USC 371 (c)(3)) <input type="checkbox"/> a. are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> b. have been transmitted by the International Bureau. <input type="checkbox"/> c. have not been made; however, the time limit for making such amendments had NOT expired. <input checked="" type="checkbox"/> d. have not been made and will not be made. <input type="checkbox"/> 8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input type="checkbox"/> 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). <input type="checkbox"/> 10. A translation of the annexes to the Int'l Prelim. Exam. Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 20. below concern document(s) or information included: <input type="checkbox"/> 11. An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98. <input type="checkbox"/> 12. An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input checked="" type="checkbox"/> 13. A First preliminary amendment . <input type="checkbox"/> 14. A Second or Subsequent preliminary amendment. <input type="checkbox"/> 15. A substitute specification. <input type="checkbox"/> 16. A change of power of attorney and/or address letter. <input type="checkbox"/> 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 & 35 USC 1.821-825. <input type="checkbox"/> 18. A second copy of the published international application under 35 USC 154(d)(4). <input type="checkbox"/> 19. A second copy of the English translation of the international application under 35 USC 154(d)(4). <input type="checkbox"/> 20. Other items or information: <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> A copy of the Notification of Missing Requirements under 35 U.S.C. 371. <input type="checkbox"/> In the event that a petition for extension of time is required to be submitted herewith, and in the event that a separate petition does not accompany this response, applicant hereby petitions under 37 CFR 1.136(a) for an extension of time of as many months as are required to render this submission timely. Any fee is authorized in 17(c).				
Date: 08 January 2002				

2007-01-08 10:00:00

U.S. APPLICATION NO. 10/030055 INTERNATIONAL APPLICATION NO. PCT/EP00/06730		ATTORNEY DOCKET NO P07484US00/BAS					
<input checked="" type="checkbox"/> 21. The following fees are submitted: <input checked="" type="checkbox"/> Basic National Fee (37 CFR 1.492 (a) (1)-(5): <div style="margin-left: 20px;"> <input type="checkbox"/> Neither Int'l Prelim. Exam. fee nor Int'l Search fee paid to USPTO \$1040 <input checked="" type="checkbox"/> Search Report has been prepared by the EPO or JPO \$ 890 <input type="checkbox"/> No Int'l Prelim. Ex. fee paid to USPTO but Int'l Search fee paid to USPTO \$ 740 <input type="checkbox"/> International preliminary examination fee paid to USPTO \$ 710 <input type="checkbox"/> Int'l Prelim. Ex. fee paid to USPTO & all claims satisfied PCT Art. 33(1)-(4) \$ 100 </div> <div style="text-align: right; margin-top: 10px;"> ENTER APPROPRIATE BASIC FEE AMOUNT = \$ 890 </div>			CALCULATIONS PTO USE ONLY				
<input type="checkbox"/> Surcharge of \$130 for furnishing the oath or declaration later than from the earliest claimed priority date (37 CFR 1.492(e)).			<input type="checkbox"/> 20 mos. <input type="checkbox"/> 30 mos. + \$				
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE				
Total Claims	20 - 20 =		X \$18 = \$				
Independent Claims	04 - 03 =	1	X \$84 = \$ 84				
<input type="checkbox"/> Multiple Dependent Claim(s) (if applicable)			+ \$280 = \$				
TOTAL OF ABOVE CALCULATIONS =			\$ 974				
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.			-				
SUBTOTAL =			\$ 974				
<input type="checkbox"/> Processing fee of \$130 for furnishing the English translation later than from the earliest claimed priority date (37 CFR 1.492(f)).			<input type="checkbox"/> 20 mos. <input type="checkbox"/> 30 mos. + \$				
TOTAL NATIONAL FEE =			\$ 974				
<input type="checkbox"/> Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) \$40 per property			+				
TOTAL FEES ENCLOSED =			\$ 974				
<i>Amount to be</i>			<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="text-align: right;"><i>Refunded</i></td> <td style="text-align: center;">\$</td> </tr> <tr> <td style="text-align: right;"><i>Charged</i></td> <td style="text-align: center;">\$</td> </tr> </table>	<i>Refunded</i>	\$	<i>Charged</i>	\$
<i>Refunded</i>	\$						
<i>Charged</i>	\$						
<input checked="" type="checkbox"/> a. A check in the amount of \$ 974 to cover the above fees is enclosed. <input type="checkbox"/> b. Please charge my Deposit Account No. 12-0555 in the amount of \$ to cover the above fees. <input checked="" type="checkbox"/> c. The Commissioner is hereby authorized to charge any additional fees required or credit overpayment to Deposit Account No. 12-0555.							
Note: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status							
SEND ALL CORRESPONDENCE TO: B. AARON SCHULMAN At the address (below) of CUSTOMER NO. 00881. LARSON & TAYLOR, PLC 1199 NORTH FAIRFAX ST. SUITE 900 ALEXANDRIA, VA 22314		SIGNATURE: <u><i>Douglas E. Jackson</i></u> NAME: Douglas E. Jackson REG. NO.: 28518 PHONE NO.: 703-739-4900 Date: 08 Jan. 2002					

10/030055

531 Rec'd PCT 08 JAN 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent

In re patent application of: MOOSER et al.

Serial No.: Unassigned

Examiner: Unassigned

Filed: On even date herewith

Art Unit: Unassigned

For: METHOD FOR THE DIAGNOSIS OR THE ...

Dckt No.: P07484US00/BAS

PRELIMINARY AMENDMENT

Assistant Commissioner of Patents

Washington, D.C. 20231

SIR:

Prior to examination, please amend the above-identified application as follows:

IN THE CLAIMS


A clean version of all pending claims is provided herewith in **Attachment A**. It will be noted that all the have been amended relative to the previously provided version as shown by the marked up version thereof in **Attachment B** provided herewith.

REMARKS

The present amendment is made to eliminate multiple dependent claims and thus eliminate the requirement for a multiple claim fee.

Respectfully submitted,

Date: 1/8/02


By: Douglas E. Jackson
Registration No.: 28,518

LARSON & TAYLOR, PLC • 1199 North Fairfax St. • Suite 900 • Alexandria, VA 22314 • (703) 739-4900

ATTACHMENT A

Clean Replacement/New Claims (entire set of pending claims)

Following herewith is a clean copy of the entire set of pending claims.

1. A method of predicting an increased risk of a patient having Alzheimer's disease or for a subject of developing AD comprising:

- a) assaying a DNA-containing biological sample for the allele of the APOE gene;
 - b) assaying the plasmatic level of protein Lp(a) or glycoprotein Apo(a),
- wherein the presence of an $\epsilon 4$ allele of the APOE gene and an increased plasmatic level of [Lp(a)]/Apo(a) indicates an increased risk for the patient having Alzheimer's disease or developing AD.

2. A method according to claim 1 wherein the level of Lp(a)/Apo(a) is assayed by means of an immunological assay, namely an immunoenzymatic assay.

3. (amended) A method according to claim 2 wherein in the Lp(a)/Apo(a) level is assayed by means of a sandwich ELISA method carrying out a first antibody against K4-type 1 and 2 repeats for capturing Lp(a) and a second antibody conjugated to horseradish peroxidase directed against K4-type 9 repeats for performing the detection of the immune complex formed thereby.

4. (amended) A method according to claim 1 comprising:

- i) amplifying the DNA in a DNA-combining biological sample from a patient or a subject with a first pair of primers which amplify at least a portion of the APOE gene; and
- ii) visualizing the amplification products of step i) and thereby assaying for the presence of the APOE $\epsilon 4$ allele.

5. (amended) A kit comprising:

- a first pair of primers which are capable of amplifying at least a portion of the APOE gene;

- a reagent for assaying the presence in a DNA sample of the APOE ϵ 4 allele;
and

- at least one antibody recognizing Lp(a)Apo(a).

6. The kit according to claim 5 wherein the said reagent is a probe specific for APOE ϵ 4.

7. (amended) The kit according to claim 5 further comprising at least one reagent for amplifying DNA.

8. (amended) The kit according to claim 5 further comprising reagents for performing polyacrylamide gel electrophoresis.

9. The kit according to claim 5 wherein said antibody is conjugated to an enzyme, namely horseradish peroxidase.

10. (amended) A therapeutic method comprising the step of using a compound capable of decreasing the plasmatic level of Lp(a) for preventing or treating the Alzheimer disease in a subject bearing at least one APO ϵ 4 allele.

11. (amended) A therapeutic method according to claim 10 wherein said compound modifies the transcription of the Apo(a) gene, namely consists of danazol or retinoic acid.

12. (amended) A therapeutic method according to claim 10 wherein said compound modifies the expression of the Apo(a) gene, and namely consists of an oligonucleotide ribozyme.

13. (amended) A therapeutic method according to claim 10 wherein said compound inhibits the production of the Apo(a)/Lp(a) protein.
14. (amended) A therapeutic method according to claim 13 wherein said compound modifies the folding of the Apo(a) protein and namely consist of an anti-oxidant inhibiting the formation of disulfide bridges.
15. (amended) A therapeutic method according to claim 13 wherein said compound modifies the glycosylation of the Apo(a) protein, and namely consist of catanospasmine.
16. (amended) A therapeutic method according to claim 13 wherein said compound modifies the binding of the Apo(a) protein to the cell surface, and namely consists of an antibiotic of the deoxystreptamine family.
17. (amended) A therapeutic method according to claim 13 wherein said compound modifies the binding of Apo(a) to Apo B100 protein, and namely consists of an analog of lysine, arginine or phenylalanine or of an anti-Apo(a) antibody.
18. (amended) A therapeutic method comprising the step of using a compound capable of inhibiting the binding of Apo(a)/Lp(a) to its receptor for preventing or treating the Alzheimer disease in a subject bearing at least one APO ϵ 4 allele.
19. (amended) A therapeutic method according to claim 18 wherein said compound inhibiting the binding of Apo(a)/Lp(a), to its receptor is a compound which blocks the binding site of Apo(a) K4-type 6-7 to the receptor triggered by cholesterol.
20. (amended) A therapeutic method according to claim 17 wherein said compound inhibiting the binding of Apo(a)/Lp(a) to its receptor is a compound which interacts with a low-density lipoprotein receptor related protein, and namely consists of a α -2 macroglobulin or a surface proteoglycan.

ATTACHMENT B

Marked Up Replacement Claims

Following herewith is a marked up copy of each rewritten claim together with all other pending claims.

1. A method of predicting an increased risk of a patient having Alzheimer's disease or for a subject of developing AD comprising:
 - a) assaying a DNA-containing biological sample for the allele of the APOE gene;
 - b) assaying the plasmatic level of protein Lp(a) or glycoprotein Apo(a),wherein the presence of an $\epsilon 4$ allele of the APOE gene and an increased plasmatic level of [Lp(a)]/Apo(a) indicates an increased risk for the patient having Alzheimer's disease or developing AD.
2. A method according to claim 1 wherein the level of Lp(a)/Apo(a) is assayed by means of an immunological assay, namely an immunoenzymatic assay.
3. (amended) A method according to claim 2 wherein in the Lp(a)/Apo(a) level is assayed by means of a sandwich ELISA method carrying out a first antibody against K4-type 1 and 2 repeats (for capturing Lp(a)) and a second antibody conjugated to horseradish peroxidase directed against K4-type 9 repeats for performing the detection of the immune complex formed thereby.
4. (amended) A method according to ~~claims 1 to 3~~ claim 1 comprising:
 - i) amplifying the DNA in a DNA-combining biological sample from a patient or a subject with a first pair of primers which amplify at least a portion of the APOE gene; and
 - ii) visualizing the amplification products of step i) and thereby assaying for the presence of the APOE $\epsilon 4$ allele.
5. (amended) A kit comprising:

- a first pair of primers which are capable of amplifying at least a portion of the APOE gene;
 - a reagent for assaying the presence in a DNA sample of the APOE ϵ 4 allele;
- and
- at least one antibody recognizing Lp(a)Apo(a).

6. The kit according to claim 5 wherein the said reagent is a probe specific for APOE ϵ 4.

7. (amended) The kit according to claim 5 or 6 further comprising at least one reagent for amplifying DNA.

8. (amended) The kit according to ~~any one of claims 5 to 7~~ claim 5 further comprising reagents for performing polyacrylamide gel electrophoresis.

9. The kit according to claim 5 wherein said antibody is conjugated to an enzyme, namely horseradish peroxidase.

10. (amended) ~~A therapeutic method comprising the step of using~~ The use of a compound capable of decreasing the plasmatic level of Lp(a) ~~for the manufacture of a medicament~~ for preventing or treating the Alzheimer disease in a subject bearing at least one APO ϵ 4 allele.

11. (amended) ~~A therapeutic method~~ The use of a compound according to claim 10 wherein said compound modifies the transcription of the Apo(a) gene, namely consists of danazol or retinoic acid.

12. (amended) ~~A therapeutic method~~ The use of a compound according to claim 10 wherein said compound modifies the expression of the Apo(a) gene, and namely consists of an oligonucleotide ribozyme.

13. (amended) A therapeutic method~~The use of a compound~~ according to claim 10 wherein said compound inhibits the production of the Apo(a)/Lp(a) protein.

14. (amended) A therapeutic method~~The use of a compound~~ according to claim 13 wherein said compound modifies the folding of the Apo(a) protein and namely consist of an anti-oxidant inhibiting the formation of disulfide bridges.

15. (amended) A therapeutic method~~The use of a compound~~ according to claim 13 wherein said compound modifies the glycosylation of the Apo(a) protein, and namely consist of catanospasmine.

16. (amended) A therapeutic method~~The use of a compound~~ according to claim 13 wherein said compound modifies the binding of the Apo(a) protein to the cell surface, and namely consists of an antibiotic of the deoxystreptamine family.

17. (amended) A therapeutic method~~The use of a compound~~ according to claim 13 wherein said compound modifies the binding of Apo(a) to Apo B100 protein, and namely consists of an analog of lysine, arginine or phenylalanine or of an anti-Apo(a) antibody.

18. (amended) A therapeutic method comprising the step of using~~The use of a compound capable of inhibiting the binding of Apo(a)/Lp(a) to its receptor for the manufacture of a medicament~~ for preventing or treating the Alzheimer disease in a subject bearing at least one APO ε4 allele.

19. (amended) A therapeutic method~~The use~~ according to claim 18 wherein said compound inhibiting the binding of Apo(a)/Lp(a), to its receptor is a compound which blocks the binding site of Apo(a) K4-type 6-7 to the receptor triggered by cholesterol.

20. (amended) A therapeutic method~~The use~~ according to claim 17 wherein said compound inhibiting the binding of Apo(a)/Lp(a), to its receptor is a compound which

interacts with LPR (a low-density lipoprotein receptor related protein), and namely consists of a α -2 macroglobulin or a surface proteoglycan.



2007-09-04 10:00:00

METHOD FOR THE DIAGNOSIS OR THE PROGNOSIS OF ALZHEIMER DISEASE
THERAPEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER DISEASE

The present invention relates to a method for the diagnosis or the
5 prognosis of Alzheimer's disease (AD).

The present invention further provides a therapy for preventing or
treating AD.

Alzheimer's disease is a brain pathology characterized by an early
dementia with a loss of cortical neurons associated with plaques of β -amyloid,
10 neurofibrillary tangles and, in most cases, an amyloid angiopathy. It is strongly
suspected that there is a genetic influence in the aetiology of Alzheimer's
disease (WO 94/01772).

This genetic component has been brought to the fore over many
years by indirect observations which suggest that the disease is inherited in
15 autosomal dominant fashion with an age-dependant penetrance in order to
explain the family links between individuals suffering from the disease. Recent
molecular genetic studies have enabled putative genes for Alzheimer's disease
to be isolated by looking for chromosome-specific polymorphic genetic markers
(Bird et al, 1989, *Neurobiology of Aging* 10, 432-434).

20 Three chromosomal localizations have been described as being
involved in the early onset familial forms (age at onset under 60 years) :
chromosome 21, chromosome 14 and chromosome 19. Two linkage studies
have suggested that the chromosomal region 19q13.2 was associated with late
onset familial forms of Alzheimer's disease (Pericak-Vance et al, *Am. J. Hum.*
25 *Genet.* (1991), 48, 1034-1050 ; Schellenberg et al, *Ann. Neurol.*, (1992), 31,
223-227). Within this chromosomal region, the group of genes for
apolipoproteins (APO) E-CI-CI'-CII is a candidate zone. Among the products of
these genes, apolipoprotein E (APOE) is involved especially in the nervous
system : APOE is present in the senile plaques and possesses a binding
30 affinity for the peptide β -A4. Strittmatter et al (*Proc. Natl. Acad. Sci.* (1993) 90,
177-181) have described an increased frequency of the ϵ 4 allele of the APOE
gene in the late onset familial forms of Alzheimer's disease. This observation
has been confirmed for the familial forms (Corder et al, *Science* (1993), 261,

921-923) and the sporadic forms of Alzheimer's disease (Corder et al, *Science* (1993), 261, 921-923 ; Saunders et al, *Neurobiology* (1993), 13, 1467-1472).

Moreover, Schellenberg et al (*Ann. Neurol.* 1992, 31:223-227) have reported a genetic association between the F allele of the apolipoprotein CII gene (TaqI restriction fragment length polymorphism (RFLP) allele) and the familial form of Alzheimer's disease.

Furthermore, the instant inventors have already reported in WO 95/24504 that the risk for a subject to develop AD is related to the presence of APO CII allele or/and the short D19S178 allele together with the APOE ϵ 4.

The authors of the instant invention have further demonstrated that the risk of developing an Alzheimer's disease is increased when a T \rightarrow G mutation is present in the promoter of the APOE gene leading to a modified expression of the APOE protein.

Furthermore, APO ϵ 4 allele has been associated with coronary atherosclerosis in AD patients (O. Kosunen et al, 1995 ; Stoke, vol. 26, n° 5).

The work of the inventors of the present invention has now led to the discovery that Apo(a) is a risk factor for Alzheimer's disease.

Human Lp(a) is a lipoprotein particle formed by the assembly of a low-density lipoprotein (LDL) particle and a carbohydrate rich highly hydrophobic protein named apolipoprotein (a) [apo(a)]. In Lp(a), one molecule of Apo(a) is covalently linked to the apoB-100 component by a disulfide bridge ; the presence of Apo(a) distinguishes Lp(a) from all other lipoprotein classes.

Besides high carbohydrate content, which constitutes ~30 % of the protein mass, Apo(a) also exhibits considerable heterogeneity in size and structure. Apo(a) is formed by three distinct structural domains, each exhibiting a high degree of homology with plasminogen. Plasminogen is formed by a protease domain and by five domains called kringles, designated kringle 1 through 5. Each kringle contains six conserved cysteine residues ; these form three disulfide bonds that provide the characteristic triple loop structure of the kringles. Apo(a) contains an inactive protease domain and one copy of kringle 5 domain- both of which exhibit ~85 % homology with the corresponding domains of plasminogen- and multiple copies of the plasminogenlike kringle 4 (K4) domain. The multiple copies of Apo(a) K4 are similar but not identical to

each other and can be divided into 10 distinct kringle types (K4 types through 10) ; their homology with plasminogen K4 ranges between 78 % and 88 %. One copy each of K4 type 1 and types 3 through 10 is present per Apo(a) particle ; K4 type 2, however, is present in a variable number of repeats (from 3 to > 40) which are therefore responsible for the size heterogeneity of Apo(a) and consequently of Lp(a).

The inventors of the instant invention have now examined whether elevated plasma levels of Lp(a) which binds to the same receptors as APOE was associated with AD and found that elevated plasma Lp(a) levels may constitute an additional risk factor for the development of AD in APOE ϵ 4 carriers.

The results of the survey performed by the inventors provide the rational for improving the diagnosis of AD, more precisely predicting an increased risk of developing AD as well as for designing innovative preventive and therapeutic strategies to fight AD.

In one aspect, the present invention provides a method of predicting an increased risk of a patient having Alzheimer's disease or for a subject of developing AD comprising :

- a) assaying a DNA-containing biological sample of a patient or a subject for the allele of the APOE gene ;
- b) assaying the plasmatic level of protein Lp(a) or glycoprotein Apo(a),

wherein the presence of an ϵ 4 allele of the APOE gene and an increased level of Lp(a)/Apo(a) indicates an increased risk for the patient having Alzheimer's disease or developing AD.

By "increased level of Lp(a)/Apo(a)" in the sense of the instant invention, it is meant that the level of Apo(a) is increased by at least 8.6 mg/dl with respect to a population of same age of healthy subjects.

Any method of measuring the plasmatic level of a protein is suitable.

Preferred embodiments include radioimmunoassays (RIA), enzyme linked immunoassays (ELISA), immunoradiometric assays (IRMA),

immunoenzymatic assays (IEMA) fluoroimmunoassays (FIA), chemiluminescent immunoassays, immunoagglutination assays (IA), etc.

The immunoassay may be of different types including sandwich assays using monoclonal and/or polyclonal antibodies.

5 The immunoassay may be performed in one step, two steps or three steps, as it is known in the art.

The determinations may be performed in liquid phase or on a solid support.

10 The antibody recognizing Lp(a)/ Apo(a) must be highly specific for Lp(a)/ Apo(a).

In a preferred embodiment, the method of the invention consists of determining the plasmatic level of Lp(a)/Apo(a) by means of a sandwich ELISA method carrying out a first antibody against K4-type 1 and 2 repeats (for capturing Lp(a)) and a second antibody conjugated to horseradish peroxidase directed against K4-type 9 repeats for performing the detection of the immune complex formed thereby.

The determination of the APOE polymorphism is performed according to any method well known in the art.

20 In one embodiment, this method comprises :

i) amplifying the DNA in a DNA-containing biological sample from a patient or a subject, with a first pair of primers which amplify at least or portion of the APOE gene ;

ii) visualizing the amplification products of step i) ;

25 and thereby determining the presence of the APOE ϵ 4 allele.

A "DNA-containing biological sample" refers to a sample of tissue or fluid suspected of containing an analyte polynucleotide from an individual including, but not limited to, e.g. plasma, serum spinal fluid, lymph fluid, the external secretions of the skin, respiratory, intestinal and genitourinary tracts, tears, saliva, blood cells, tumors, organs, tissue and samples of *in vitro* cell culture constituents.

Step i) is performed in a manner known *per se* involving a nucleic acid amplifying method by means of a pair of primers specifically hybridizing to the region flanking the nucleic acid sequence to be amplified.

5 The method is preferably a DNA amplifying method, namely PCR (Innis et al, 1990 ; PCR protocols : A guide to methods and Applications (Academic Press, San Diego, Californie).

Suitable primers are described in the art and namely include those described by Hixson et al (1990), *J. Lipid Res.* 31, 545-548. Reagents and hardware for conducting PCR are commercially available.

10 Other suitable methods are well-known and widely practiced in the art (see eg US 4 683 195 and US 4 683 202 and Wu et al, 1989 (Genomics 4 560-569)).

Step ii) is conducted by detecting the hybridization of the amplified products with a polynucleotide probe which forms a stable hybrid with that of the target sequence, under stringent hybridization and wash conditions.

15 Probes for APOE ϵ 4 are derived from the APOE ϵ 4 allele region and span all or a portion of said region and allow specific hybridization to the APOE ϵ 4 region.

20 The length of the probe is advantageously of at least 30 nucleotides.

The probes include an isolated polynucleotide attached to a label or a reporter molecule.

25 According to a further aspect, the instant invention provides a kit for predicting an increased risk of a patient having AD or for a subject of developing AD, wherein the kit comprises :

- a first pair of primers which are capable of amplifying at least a portion of the APOE gene ;
- a reagent for assaying the presence in a DNA sample of the APOE ϵ 4 allele ;
- at least one antibody recognizing Lp(a)/Apo(a).

30 Advantageously, the reagent is a probe specific for APOE ϵ 4.

The kit may also comprises at least one reagent for amplifying DNA. The reagent is advantageously a polymerase enzyme capable of performing polymerase chain reaction. One example is Taq polymerase.

5 The kit of the invention may also comprise a reagent for performing polyacrylamide gel electrophoresis.

In a preferred embodiment, the antibody is a monoclonal antibody conjugated to an enzyme, namely horseradish peroxidase.

10 The present invention further provides a therapy for preventing or treating Alzheimer disease.

Thus, in another aspect, the invention provides the use of a compound capable of decreasing the plasmatic level of Lp(a) for the manufacture of a medicament for preventing or treating Alzheimer disease in a subject bearing at least one APO ϵ 4 allele.

15 In a first embodiment, the compound is a modifier of the transcription of the Apo(a) gene.

Preferred examples are retinoic acid (*Biochem. Biophys. Res. Commun* 1997, Sept 8, 238(1) :48-52) and danazol (*Biochem. Biophys. Res. Commun* 1996 Oct. 14, 227(2) : 570-5).

20 In a second embodiment, the compound is a modifier of the expression of the Apo(a) gene.

The compound is typically an oligonucleotide ribozyme (*Circulation*, 1998 Nov. 3 (18) : 1898-909).

25 These compounds result in a modified, preferably a decreased synthesis of Apo(a).

In a third embodiment, the compound modifies the folding of the Apo(a) protein.

The compound is typically a compound able to block the formation of disulfide bridges, namely an anti-oxidant.

30 In a fourth embodiment, the compound modifies the glycosylation of the Apo(a) protein.

One example of that type is catanospermine (*J. Bio/Chem.* 1997, Feb. 21, 272 (8) : 5078-55).

10030055.034102

In a fifth embodiment, the compound modifies the binding of the Apo(a) protein to the cell surface.

The compound is typically an antibiotic, namely of the deoxystreptamine family, such as neomycine (*J. Lipid. Res.* 1996 Oct., 37(10) : 2055-64).

In a sixth embodiment, the compound modifies the binding of Apo(a) to the Apo B100 protein.

The compound may consist of an analog of lysine (for example, epsilon amino caproic acid (*Arterioscler. Thromb. Vasc. Biol.* 1998 Nov., 18(11) : 1738-44), arginine or phenylalanine (*Biochemistry*, 1998 May 26, 37(21) : 7892-8), or of an anti-Apo(a) antibody.

Alternatively, the compound may consist of an antibody recognizing Apo(a) (*J. Biol. Chem.*, 1994 Nov. 18, 269(46) :28716-23).

The compounds according to the third, fourth, fifth and sixth embodiment result in a decreased production of Apo(a)/Lp(a).

In a further aspect, the invention provides the use of a compound inhibiting the binding of Apo(a)/Lp(a) to its receptor for the manufacture of a medicament for preventing or treating the Alzheimer disease in a subject bearing at least one APO ϵ 4 allele.

In a first embodiment, the compound is one which blocks the binding site of Apo(a) K4.type 6-7 to the receptor triggered by cholesterol (*J. Biol. Chem.* 1996 Dec.13, 271 (50): 32096-104).

In a second embodiment, the compound is one LPR (low-density lipoprotein receptor related protein).

Typically, the compound consists of an α -2 macroglobulin or a surface proteoglycan, namely heparinase, chondroitinase ABC or sodium chlorate (FASEB J, 1998 Dec., 12(15) : 1765-76).

The following non limiting examples and the enclosed figures illustrate the invention.

LEGENDS OF FIGURES

Figure 1 illustrates the relationship between the odds ratio (OR) and the age of onset of patients having AD in presence of plasma Lp(a) levels > 8.6 mg/dl in non-APOE ϵ 4 carriers (broken line) and in APOE ϵ 4 carriers (solid line). APOE was genotyped as described in Hixson et al, J. Lipid. Res. 31:545-548) and quantification of plasma Lp(a) levels was performed using an ELISA assay and monoclonal antibodies of well-defined specificity (Marcovina et al, *Clin. Chem.* 1995, 41/2:246-255). The odds ratio were calculated using multivariate logistic regression analysis on log-transformed plasma Lp(a) levels. Confidence intervals are given in the text.

Figure 2 shows the pattern observed in immunodetection of Apo(a) in human brain with AD-type cortical changes. Brains from two subjects with AD-type cortical changes were examined for the presence of Apo(a) using IgG-a5 antibody, as described hereunder in Methods.

METHODS

Clinical study

Participants to the study were of Caucasian origin and were recruited in Europe. They were thoroughly investigated clinically. The diagnosis of AD was made to the DSM-III-R criteria (American Psychiatric Association, 1987) and NINCDS-ADRDA (Mc Kahn et al, *Neurol.*, 1984, 34:939-944), whereas subjects were categorized as non-demented controls in absence of any DSM-III-R criteria for dementia and the presence of cognitive functions preserved in their integrity. Recruitment of controls took place between February and August, 1993, whereas subjects with AD were recruited between May, 1994 and June, 1995. All female participants were post-menopausal. For each participant, a total of 20 ml of blood was collected on EDTA, stored on ice and subjected to centrifugation within 4 hours. Plasma was isolated and aliquots were stored at -80°C .

Laboratory methods

Plasma levels of Lp(a) were quantitated on samples which had never been thawed before using an ELISA assay (Marcovina et al, *Clin. Chem.*, 1995, 41/2:246-255). This method utilizes IgG-a6 as capture antibody and IgG-a40 conjugated to horseradish peroxidase as detecting antibody. IgG-6 recognizes the Apo(a) K4-type 1 and 2 repeats. To determine the size of the Apo(a) isoforms, plasma proteins were size-fractionated on a 2 % SDS-agarose gel and the size of the Apo(a) isoforms was determined based on their migration relative to well-characterized standards (Mooser et al, *Am. J. Hum. Gen.* 1997, 61:402-417). In addition, the inventors characterized the (TTTTA)_n pentanucleotide repeat polymorphism in the 5' flanking region of the Apo(a) gene (Mooser et al, *Human. Mol. Gen.* 1995, 4:173-181) and performed APOE genotyping (Hixson et al, *J. Lipid.* 1990, 31:545-548).

Immunohistochemical analysis of Apo(a) in human brain.

A total of 15 autopsy cases were examined. Brains were fixed for 4 weeks in 10 % formalin and ~ 3x2x1 cm blocks were excised from the frontal and parietal associative areas (Brodmann's areas 8-9 and 39-40, respectively) and from the temporal region. Temporal blocks included the hippocampus and entorhinal cortex. Blocks were embedded in paraffin, and 5 µm sections were used for histological and immunohistochemical analysis. Senile plaques were stained with Thioflavin S technique and examined by immunohistochemistry using a monoclonal antibody (M872) directed against β-amyloid (DAKO, Zug, Switzerland), whereas neurofibrillary tangles were stained using the Gallyas silver technique. Among the 15 autopsy cases examined, ten cases met the quantitative histological criteria for neuropathological diagnosis of AD, as proposed by Khachaturian, (*Arch. Neurol.*, 1985, 42:1097-1105), whereas no AD-type cortical changes were detected in the remaining five cases. For immunodetection of Apo(a), sections were deparaffinized, rehydrated and treated with 0.3 % methanolic peroxide for 30 minutes in order to eliminate endogen peroxidase activity. Sections were then treated with diluted normal rabbit serum (1:100) at 37°C for 30 minutes, and incubated overnight at 4°C with IgG-a5 (diluted to 50 µg/ml) or IgG-a40 (diluted to 10 µg/ml). Detection

was performed using the ammonium-nickel-sulfate technique, or the ABC kit according to the recommendations of the manufacturer (DAKO), followed by counterstaining with hematoxinilin. Control sections were examined after omission of the primary antibody or after incubation with an irrelevant monoclonal antibody.

Statistical analysis

Statistical analyses were performed with the SAS software release 6.10 (SAS Institute Inc, Cary, NC)). Means and standard deviations (SD) were calculated for quantitative variables. Categorical data were tested using the Pearson's χ^2 or Fisher's exact test when necessary. Multivariate logistic regression model was used to estimate adjusted OR and 95 % CI. Covariates taken into account were age and gender.

RESULTS

Levels of lipoprotein(a)/[Lp(a)] were quantitated in plasma samples collected from 296 non-demented control individuals and 285 subjects with Alzheimer disease including 200 (70,2 %) subjects who had dementia diagnosed at or after age 65 years (late-onset AD).

Participants were partitioned according to the presence of at least one APOE ϵ 4 allele, and their characteristics are described in the Table hereunder. As expected, the proportion of APOE ϵ 4 carriers among demented subjects (170/285, 60 %) was higher than in the control group [74/296, 25 % ; odds ratio (OR) 4.4, 95 % confidence interval (CI) 3.1 – 6.4 ; $p < 0,00001$]. The proportion of males was lower than females in the four groups. Demented subjects were older than controls. However, among controls or AD subjects, age was similar for APOE ϵ 4 carriers and non-APOE ϵ 4 carriers.

As expected, in the four groups, the distribution of plasma Lp(a) levels was markedly skewed towards lower values, whereas log-transformed values were more normally distributed.

Among APOE ϵ 4 carriers, plasma Lp(a) levels were higher in subjects with dementia than in controls [9.8 mg/dl vs 6.9 mg/dl (median), $p = 0.049$, Table] hereunder, with a smaller proportion of subjects with plasma

Lp(a) levels < 10 mg/dl (51 % vs 66 %, $p=0.03$). The difference in the distribution of plasma Lp(a) levels between demented and non-demented APOE $\epsilon 4$ carriers was very similar to the one reported for subjects with or without coronary artery disease (Sandholzer et al, *Arterioscl. Thromb. Vas. Biol.*, 1992, 12:1214-1216). In contrast, among non-APOE $\epsilon 4$ carriers, median plasma Lp(a) level was similar for subjects with or without dementia [8,6 mg/dl vs 8.5 mg/dl, $p = 0.82$]. This observation suggested that the difference in plasma Lp(a) levels between demented and non-demented APOE $\epsilon 4$ carriers was not due to dementia itself, nor to the age difference between these two groups.

Binding of Lp(a) to receptors which also have APOE as ligand (VLDL-R (Argraves et al, *J. Clin. Invest.*, 1997, 100:2170-2181), LRP (März et al, *FEBS*, 1993, 325:271-275) and GP330/megalin (Niemeier et al, *Arterioscler Thromb. Vas. Biol.* 1998 ; La Ferla et al, *J. Clin. Invest.*, 1997, 100:310-320) may depend on the size of apolipoprotein(a) [Apo(a) (März et al, above), the distinctive and highly polymorphic glycoprotein covalently attached to apolipoprotein B of LDL to form Lp(a) (Utermann et al, *Science*, 1989, 246:904-910). The size of the Apo(a) isoform is dictated by the number of K4 copies within the Apo(a) gene. To address this question, the inventors examined the size of the Apo(a) isoforms in the four groups of subjects. Overall, the proportion of subjects who had no Apo(a) isoform detectable by immunoblot analysis was 10 % (57/581). The frequency distribution of the size of the Apo(a) isoform for subjects who had only one band detectable, or the smaller Apo(a) isoform for subjects with two detectable bands, was similar between the four groups (table hereunder). As expected, an inverse relationship was observed between the size of the Apo(a) isoforms and plasma Lp(a), and this relationship was similar for the four groups under study.

Next, the inventors characterized the (TTTTA)₅₋₁₂ polymorphism located in the 5' flanking region of the Apo(a) gene. This polymorphism is in strong linkage disequilibrium with the size of the Apo(a) gene and sequences which impact on plasma levels of Lp(a). As was observed in another populations, the most frequent allele had 8 copies of the TTTTA repeat (69,3 %) whereas alleles containing 10 copies (14,9 %), 9 copies (13,9 %), 11

copies(1,6 %) were less frequent. The frequency of alleles containing 5, 6, 7 or 12 copies of the TTTTA repeat was less than 0,5 % in this population. No significant difference in the distribution of the TTTTA alleles was observed between the four groups. Taken together, these analyses indicated that the association between AD and Apo(a) was not restricted to a subset of Apo(a) isoforms or specific alleles at the *Apo(a)* gene.

To determine the risk of having AD in presence of elevated plasma levels of Lp(a), the inventors performed multivariate logistic regression analysis. A threshold of 8.6 ml/dl was chosen, which was the median plasma Lp(a) level for the entire group. No change in OR was observed in non-APOE $\epsilon 4$ carriers over the age examined (figure1). In contrast, in APOE $\epsilon 4$ carriers, the presence of plasma Lp(a) levels > 8.6 mg/ml was associated with a progressive increasing risk of AD which rose from 1.2 [95 % confidence interval, 0.7-2.1] in subjects aged > 65 (n = 68 controls and 143 AD subjects) to 2.1 (1.1-4.1) for subjects aged > 70 years (n = 59 and 94), 5.1 (1.9-13.8) for subjects aged > 75 years (n = 48 and 42) and 15.2 (1.7-135) for subjects aged > 80 (n = 30 and 9). Similar results were obtained when subjects with early onset were excluded from the analysis or when different thresholds for plasma Lp(a) levels were selected.

Lp(a) has been identified in plasma from a restricted number of species including hedgehog, great apes and humans. Apo(a) that circulates in plasma is synthesized by the liver. In addition, Apo(a) transcripts have been identified in monkey testis and brain and, to an lesser extent, in lung and adrenals. However, whether Apo(a) glycoprotein is present in human or monkey brains is not known. To examine whether the association between Lp(a) and AD had a morphological basis, the inventors performed immunohistochemical analysis on 10 human brains with pathologically proven AD-type cortical changes, and five brains with no sign of AD. Apo(a) was immunodetected using mouse monoclonal antibodies IgG-a5 and IgG-a40, which are directed against the N-terminus (K4-type 2) and the C-terminus (K4-type 9) of Apo(a) respectively, and which do not cross-react with plasminogen. The signal was specific, as both antibodies gave the same pattern and no signal was detected in control sections where the primary antibody was

omitted, or when an irrelevant antibody was used. In all AD cases, Apo(a) immunoreactivity was detected in senile plaques (figure 2, panel A), in a subset of neurons with neurofibrillary tangles and granulovacuolar degeneration and in reactive microglia and astrocytes (panels B and C). A small proportion of apparently unchanged neurons were also stained (panel C). In addition, a strong Apo(a) immunoreactivity was detected in endothelial cells of leptomeningeal and parenchymal vessels. In brains from patients without AD-type cortical changes, a strong Apo(a) immunoreactivity was observed on endothelial cells whereas only a few neurons showed Apo(a) immunopositivity. These neurons were without histologically detectable changes. These analyses were suggested that Apo(a) may be implicated in neuronal degeneration present in AD.

Various scenarios can be proposed to account for the APOE ϵ 4 specific association between elevated plasma Lp(a) levels and AD. APOE ϵ 4 carriers are at higher risk of developing AD after brain insult like trauma or stroke. On the other hand, elevated plasma levels of Lp(a) have been associated with cerebral infarctions. It is conceivable that such vascular injuries have none or minimal functional consequences in non-APOE ϵ 4 carriers. In contrast, because neuronal plasticity and capacity of regeneration is limited in APOE ϵ 4 carriers, such vascular injuries may progressively lead to the development of AD. As such, this scenario would reinforce the hypothesis of vascular factors in the pathogenesis of AD. It is also conceivable that binding of Lp(a) –or the fraction of Lp(a) particles which carry APOE- may contribute to increased cholesterol delivery to neurons, which may be toxic, as suggested by the beneficial effect for neurons of cholesterol deprivation *in vitro*. Finally, Apo(a) may interfere with other kringle-containing proteins, like urokinase plasminogen activator or thrombin.

In summary, the data are consistent with elevated plasma levels of Lp(a) acting as a modifier trait in the development of APOE ϵ 4 –associated AD.

CLAIMS

1. A method of predicting an increased risk of a patient having Alzheimer's disease or for a subject of developing AD comprising :

a) assaying a DNA-containing biological sample for the allele of the APOE gene ;

b) assaying the plasmatic level of protein Lp(a) or glycoprotein Apo(a),

wherein the presence of an $\epsilon 4$ allele of the APOE gene and an increased plasmatic level of [Lp(a)]/Apo(a) indicates an increased risk for the patient having Alzheimer's disease or developing AD.

2. A method according to claim 1 wherein the level of Lp(a)/Apo(a) is assayed by means of an immunological assay, namely an immunoenzymatic assay.

3. A method according to claim 2 wherein the Lp(a)/Apo(a) level is assayed by means of a sandwich ELISA method carrying out a first antibody against K4-type 1 and 2 repeats (for capturing Lp(a)) and a second antibody conjugated to horseradish peroxidase directed against K4-type 9 repeats for performing the detection of the immune complex formed thereby.

4. A method according to claims 1 to 3 comprising :

i) amplifying the DNA in a DNA-containing biological sample from a patient or a subject with a first pair of primers which amplify at least a portion of the APOE gene ;

ii) visualizing the amplification products of step i) and thereby assaying for the presence of the APOE $\epsilon 4$ allele.

5. A kit comprising :

- a first pair of primers which are capable of amplifying at least a portion of the APOE gene ;

- a reagent for assaying the presence in a DNA sample of the APOE ϵ 4 allele ;
- at least one antibody recognizing Lp(a)/Apo(a).

5 6. The kit according to claim 5 wherein the said reagent is a probe specific for APOE ϵ 4.

7. The kit according to claim 5 or 6 further comprising at least one reagent for amplifying DNA.

10

8. The kit according to any one of claims 5 to 7 further comprising reagents for performing polyacrylamide gel electrophoresis.

15

9. The kit according to claim 5 wherein said antibody is conjugated to an enzyme, namely horseradish peroxidase.

20

10. The use of a compound capable of decreasing the plasmatic level of Lp(a) for the manufacture of a medicament for preventing or treating the Alzheimer disease in a subject bearing at least one APO ϵ 4 allele.

25

11. The use of a compound according to claim 10 wherein said compound modifies the transcription of the Apo(a) gene, and namely consists of danazol or retinoic acid.

30

12. The use of a compound according to claim 10 wherein said compound modifies the expression of the Apo(a) gene, and namely consists of an oligonucleotide ribozyme.

13. The use of a compound according to claim 10 wherein said compound inhibits the production of the Apo(a)/Lp(a) protein.

14. The use of a compound according to claim 13 wherein said compound modifies the folding of the Apo(a) protein and namely consists of an anti-oxidant inhibiting the formation of disulfide bridges.

5 15. The use of a compound according to claim 13 wherein said compound modifies the glycosylation of the Apo(a) protein, and namely consist of catanospermine.


10 16. The use of a compound according to claim 13 wherein said compound modifies the binding of the Apo(a) protein to the cell surface, and namely consists of an antibiotic of the deoxystreptamine family.

15 17. The use of a compound according to claim 13 wherein said compound modifies the binding of Apo(a) to Apo B100 protein, and namely consists of an analog of lysine, arginine or phenylalanine or of an anti-Apo(a) antibody.

20 18. The use of a compound capable of inhibiting the binding of Apo(a)/Lp(a) to its receptor for the manufacture of a medicament for preventing or treating the Alzheimer disease in a subject bearing at least one APO ε4 allele.

25 19. The use according to claim 18 wherein said compound inhibiting the binding of Apo(a)/Lp(a), to its receptor is a compound which blocks the binding site of Apo(a) K4-type 6-7 to the receptor triggered by cholesterol.

30 20. The use according to claim 17 wherein said compound inhibiting the binding of Apo(a)/Lp(a), to its receptor is a compound which interacts with LPR (low-density lipoprotein receptor related protein), and namely consists of an α-2 macroglobulin or a surface proteoglycan.

FIG.1




Fig. 2

DECLARATION FOR USA PATENT APPLICATION

(including Design and National Stage PCT)

Attorney's Docket ID: _____

As a below named inventor, I hereby declare that:

My residence, mailing address and citizenship are as stated below adjacent to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought

on the invention entitled: Method for the diagnosis or the prognosis of Alzheimer disease therapeutic composition for preventing or treating Alzheimer disease
the specification of which:

_____ is attached hereto.

(or)

was filed on 7 JULY 2000as U.S. Application No. or PCT International Application No. PCT/EP00/06730

and (if applicable) was amended on _____

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below, where priority is not claimed, any foreign application for patent or inventor's certificate, or any PCT International application, having a filing date before that of the application on which priority is claimed. (☐ ADDITIONAL APPLICATIONS IDENTIFIED ON ATTACHED SHEET)

Prior Foreign Application No.

Country

Day/Month/Year Filed

Priority Not Claimed99401742.4EUROPE09/07/99YESI hereby claim the benefit under 35 U.S.C. 120 of any U.S. application(s), or 365(c) of any PCT application designating the U.S., listed below; and insofar as the subject matter of each claim of this application is not disclosed in the prior U.S. or PCT application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT filing date of this application. (☐ ADDITIONAL APPLICATIONS IDENTIFIED ON ATTACHED SHEET)

U.S. or PCT Parent Application No.

Parent Filing Date (Day/Month/Year)

Parent Patent No. (if applicable)

As a named inventor, I hereby appoint the registered practitioners of **LARSON & TAYLOR, PLC** associated with Customer Number 000881 to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. Direct all correspondence to that Customer Number.Direct all telephone calls to _____
at TEL (703) 739-4900 (Fax: 703-739-9577) e-mail: _____

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1000 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon

SOLE OR FIRST INVENTOR		Citizenship	<u>SWISS</u>
Given Name (first and Middle [if any]) <u>Vincent</u>		Family Name or Surname	<u>MOOSER</u>
Full Mailing Address <u>Rue du Bugnon 46 - CHUV - 1011 LAUSANNE - SUISSE</u>			
Residence - City, State/Country (if different from PO address) <u>The same as above</u> <u>CHV</u>			
SIGN AND DATE HERE Inventor's Signature <u>Mooser</u>		Date	<u>24/01/02</u>

SECOND JOINT INVENTOR (if any)		Citizenship	<u>FRENCH</u>
Given Name (first and Middle [if any]) <u>Nicole</u>		Family Name or Surname	<u>HELBECQUE</u>
Full Mailing Address <u>10 rue Félix Faure - 59750 MARCQ EN BAROEUL - FRANCE</u>			
Residence - City, State/Country (if different from PO address) <u>The same as above</u> <u>FRX</u>			
SIGN AND DATE HERE Inventor's Signature <u>N. Helbecque</u>		Date	<u>03/02/02</u>

THIRD JOINT INVENTOR (if any)		Citizenship	<u>FRENCH</u>
Given Name (first and Middle [if any]) <u>Philippe</u>		Family Name or Surname	<u>AMOUYEL</u>
Full Mailing Address <u>75 rue du Quesne - 59700 MARCQ EN BAROEUL - FRANCE</u>			
Residence - City, State/Country (if different from PO address) <u>The same as above</u> <u>FRX</u>			
SIGN AND DATE HERE Inventor's Signature <u>Philippe Amouyel</u>		Date	<u>07/01/02</u>

FOURTH JOINT INVENTOR (if any)		Citizenship	
Given Name (first and Middle [if any])		Family Name or Surname	
Full Mailing Address			
Residence - City, State/Country (if different from PO address)			
SIGN AND DATE HERE Inventor's Signature		Date	